Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Piperonyl Butoxide”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Mechanistic study on liver tumor promoting effects of piperonyl butoxide in rats.

Piperonyl butoxide, alpha-[2-(2-butoxyethoxy)ethoxy]-4,5-methylenedioxy-2-propyltol uene, is a widely used pesticide-synergist. Recently, results were reported indicating that piperonyl butoxide is a hepatocarcinogen in rat. Since the underlying mechanism was not elucidated, we examined the effects on rat liver cells in detail. For this purpose male F344 rats were administered piperonyl butoxide mixed in the diet at concentrations of 0 (negative control), 0.05, 0.2 or 2% for 2 days, 1, 2, and 4 weeks. As a positive control, phenobarbital was administered to rats for up to 4 weeks as a 0.1% solution in the drinking water. Increased liver weight, centrilobular hepatocellular hypertrophy due to increased smooth endoplasmic reticulum, decreased numbers and areas of connexin 32-positive spots per hepatocyte, and increased cell proliferation were observed in rats treated with 0.2 and 2% piperonyl butoxide. Similar results were obtained for 0.1% phenobarbital treated rats. Hepatocellular necrosis suggestive of hepatotoxicity was also observed in the 2% piperonyl butoxide group. These results indicate that the promoting mechanism of piperonyl butoxide in hepatocarcinogenesis is similar to that of phenobarbital, involving an ability to induce CYP isoenzymes and inhibit gap junctional intercellular communication. In addition, increased cell proliferation following hepatocellular necrosis may also play a role at high doses.

Animals↗

Anticonvulsant activity and neurotoxicity of piperonyl butoxide in mice.

Piperonyl butoxide, a microsomal monooxygenase inhibitor, administered intraperitoneally to mice exerts peak anti-maximal electroshock activity and peak neurotoxicity at 5 and 7h, respectively. The median neurotoxic dose is 1,690 mg/kg. In the maximal electroshock seizure test, the median effective dose (ED50) is 457 mg/kg and the protective index (PI) is 3.69. In the subcutaneous pentylenetetrazol test, the ED50 is 443 mg/kg and the PI is 3.81. Piperonyl butoxide prevents seizure spread and elevates seizure threshold. Its PI compares favorably with PIs of clinically useful anticonvulsants.

Animals↗

Changes of hexachlorobutadiene nephrotoxicity after piperonyl butoxide treatment.

The effects of piperonyl butoxide on hexachlorobutadiene (HCBD) nephrotoxicity were measured. The time course and severity of toxicity were affected. Five hours after either piperonyl butoxide or HCBD glomerular filtration rate (GFR) was decreased; at 24 h GFR had recovered for the piperonyl butoxide group but continued to fall in the HCBD group. The group treated with piperonyl butoxide and HCBD had the same GFR as the group treated with just HCBD. At 24 h after HCBD the piperonyl butoxide pretreated group was not different from the oil pretreated controls. At 48 h after HCBD, reabsorbtion of water and glucose was more severely impaired in the group pretreated with piperonyl butoxide. These results support the hypothesis that HCBD metabolites are involved in renal tubular dysfunction.

Animals↗

Lack of genotoxicity of piperonyl butoxide.

The genotoxicity of piperonyl butoxide has been investigated in bacterial mutation assays using tester strains TA98, TA100, TA1535, TA1537 and TA1538. The assays were conducted both with and without metabolic activation. Piperonyl butoxide was tested for mutation with and without metabolic activation in the CHO/HGPRT assay. Chromosomal aberrations were investigated also using Chinese hamster ovary (CHO) cells and effects on DNA were evaluated by in vitro unscheduled DNA synthesis (UDS) test using rat liver primary cell cultures. Piperonyl butoxide was not shown to be genotoxic in any assay system. The data presented supports the view that the liver tumors observed in rodents at dose levels above the maximally tolerated dose (MTD) result from a secondary non-genotoxic mechanism.

Animals↗

Subacute toxicity of piperonyl butoxide in ICR mice.

Piperonyl butoxide, alpha-[2-(2-butoxyethoxy)ethoxy]-4,5-methylenedioxy-2-propyltol uene, is a pesticide synergist. ICR mice of both sexes were maintained on diet containing 0, 0.1, 0.3 or 0.9% of piperonyl butoxide for 20 days. At the end of the experimental period, they were necropsied. Selected organs were weighed and serum chemistries were analyzed. In male and female mice of the 0.9% group, body weight, kidney and spleen weight were depressed in comparison to those of control group. Liver weight of the 0.3 and 0.9% group of both sexes were significantly higher than those of control group. Mice of the 0.9% group of both sexes had increased serum levels of cholesterol, total protein, gamma-glutamyl transpeptidase. Histological examination of livers from mice of the 0.9% group by light microscopy showed enlarged hepatocytes, anisonucleosis and single cell necrosis. The results indicated that subacute toxicity of piperonyl butoxide in ICR mice was directed primarily at liver.

Animals↗

Sub-acute toxicity of piperonyl butoxide in F344 rats.

Piperonyl butoxide, alpha-[2-(2-Butoxyethoxy)ethoxy]-4,5-methylenedioxy- 2-propyltoluene, is a pesticide synergist. F344 rats of both sex were maintained on diets containing 0, 0.6, 1.2 or 2.4% of piperonyl butoxide for 13 weeks. At the end of experimental period, they were necropsied. Selected organs were weighted and serum was analyzed by clinical chemistry. In male and female rats of the 2.4%-group, body weight gains were depressed, macroscopically, hepatomegaly was marked and liver weights were significantly higher than those of the control group. In male and female rats of all treated groups, relative kidney weights were significantly increased in a dose-dependent manner. Rats of the 2.4%-group had increased levels of albumin, cholesterol, urea nitrogen and gamma-glutamyl transpeptidase. Examination of livers of the male 2.4%-group by light microscopy showed enlarged hepatocytes with glassy cytoplasm and fatty deposition. On occasion, there was coagulative necrosis of a few hepatocytes in the periportal area and oval cell proliferation. The kidney of treated rats showed atrophy of epithelium in the proximal convoluted tubules. These results indicated that toxicity of piperonyl butoxide in rats was directed primarily to the liver and kidney.

Animals↗

Behavioural effects of piperonyl butoxide in male mice.

Piperonyl butoxide was administered to male mice from 5 to 12 weeks of age in the diet at levels of 0 (control), 0.15, 0.30, and 0.60%, and some behavioural parameters were measured. The animals performed three trials in multiple water T-maze at 10 weeks of age, and the number of errors was significantly decreased in treatment groups on the 3rd trial, while there was no biologically significant effect of piperonyl butoxide on maze learning. The motor activity of the exploratory behaviour was measured by ANIMATE AT-420 at 8 and 11 weeks of age. At 8 weeks of age, some parameters were increased in the 0.30% group, while there was no consistent compound- or dose-related effect. At 11 weeks of age, some parameters were different in treatment groups, and there were biologically consistent significant effects; i.e., number of movements, movement time, total distance, average speed, and number of turnings increased. From these results, piperonyl butoxide showed adverse effects on the motor activity of the exploratory behaviour in male mice.

Animals↗

Near UV quantum yields for rotenone and piperonyl butoxide.

Rotenone and piperonyl butoxide (PBO) mixtures, so-called "synergized" rotenone, are invaluable in fisheries management where they are used to protect the habitat of endangered, native species and promote desirable gamefish populations. Continued use of synergized rotenone is threatened by inadequate control of persistence in surface water, especially where drinking water supplies are impacted. The photochemical kinetics of these chemicals were studied in the laboratory with a goal to better understand their fate in natural water. Disappearance quantum yields (phi) were determined in polychromatic light from fluorescent lamps emitting maximally at 350 nm. Rotenone, PBO and trifluralin, an actinometer, were irradiated as aqueous solutions at 25 or 50 microg L(-1) and the piscicides were determined by electrospray-liquid chromatography-mass spectrometry (ESI-LC-MS). In the photoreactor rotenone and PBO photodegraded with first-order half-lives of 500 and 220 min, respectively, and corresponding quantum yields of 0.00015 and 0.034. Rotenone absorbs sunlight strongly, while PRO does not. Differences in spectal overlap tended to counteract the disparities in phi and, in general, mathematical modeling indicates moderately rapid direct photolysis rates for both substances in surface water.

Insecticides↗

Developmental toxicity study of piperonyl butoxide in CD rats.

Piperonyl butoxide was administered to pregnant rats by gavage at a level of 0 (control), 630, 1065, and 1800 mg/kg bw on days 11-12 of gestation. The animals were killed on day 20 of gestation. Average maternal body weight gain (gestational days 11-20) was significantly reduced in the 1065 and 1800 mg/kg bw groups. Total resorption rate was significantly increased in the 1800 mg/kg bw group and those effects were significantly dose-related. The average fetal body weight of each sex was significantly reduced in the 1065 and 1800 mg/kg bw groups. External limb deformity (oligodactyly, syndactyly, and polydactyly) was significantly increased in the 1065 and 1800 mg/kg bw groups in a dose-related manner. The dose levels of piperonyl butoxide in the present study produced limb deformities in rats.

Animals↗

Developmental toxicity evaluation of piperonyl butoxide in CD-1 mice.

Piperonyl butoxide was administered to pregnant mice by gavage at a level of 0 (control), 1065, 1385 and 1800 mg/kg body weight only on day 9 of gestation. The animals were sacrificed on day 18 of gestation. Early and late foetal deaths were significantly increased in the higher dose groups and those effects were significantly dose-related. The average body weights of male and female foetuses were significantly reduced in a dose-related fashion. The external malformation of oligodactyly in forelimbs was significantly increased in higher treatment groups in a dose-related manner. The dose levels of piperonyl butoxide in the present study produced adverse effects on developmental parameters.

Abnormalities, Drug-Induced↗

Human in vivo percutaneous absorption of pyrethrin and piperonyl butoxide.

In order to determine the human in vivo percutaneous absorption of pyrethrin and piperonyl butoxide, a commercial formulation containing either [14C]pyrethrin (3.8 mCi/mmol) or [14C]piperonyl butoxide (3.4 mCi/mmol) was applied to the ventral forearm of six human volunteers. The formulation contained 0.3% pyrethrin and 3.0% piperonyl butoxide. Spreadability studies showed that concentrations of 5.5 micrograms pyrethrin/cm2 and 75.8 micrograms piperonyl butoxide/cm2 (used in this study) would be consistent with levels found in actual use. The forearms were thoroughly cleansed with soap and water 30 min after application (as recommended for actual use). Percutaneous absorption was determined by urinary cumulative excretion following dose application. With a 7-day urinary accumulation, 1.9 +/- 1.2% (SD) of the dose of pyrethrin and 2.1 +/- 0.6% of the dose of piperonyl butoxide applied was absorbed through the forearm skin. 1 hr after application blood samples contained no detectable radioactivity. The percutaneous absorption of pyrethrin and piperonyl butoxide from the scalp was calculated to be 7.5% of the applied dose for pyrethrin and 8.3% for piperonyl butoxide. The calculated half-life of 14C excretion was 50 hr for pyrethrin and 32 hr for piperonyl butoxide. The data should be of relevance to appropriate risk assessment in extrapolating animal data to humans.

Administration, Cutaneous↗

Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications.

The effect of the cytochrome P450 inhibitor, piperonyl butoxide on the pharmacokinetics and anthelmintic efficacy of the benzimidazole compound fenbendazole was studied in sheep and goats. Pretreatment of goats with the inhibitor caused a greater than three-fold increase in the relative bioavailability of fenbendazole and fenbendazole sulphoxide. A pharmacokinetic dose titration study was carried out in sheep with fenbendazole (5 mg kg-1) and piperonyl butoxide administered orally at 0, 15, 31, 63, 125 and 250 mg kg-1. The AUC of fenbendazole and the sulphoxide were significantly increased when fenbendazole was co-administered with piperonyl butoxide at dose rates equal to or higher than 31 mg kg-1. Peak plasma concentrations (Cmax) and mean residence time (MRT) were also significantly increased. The efficacy of the combination was assessed in sheep against two species of benzimidazole-resistant abomasal nematodes; Ostertagia circumcincta and Haemonchus contortus. The percentage reduction in the total number of O. circumcincta worms was 7.9% (fenbendazole) and 97.8% (fenbendazole-piperonyl butoxide). For H. contortus, the percentage reduction was 84.8% (fenbendazole) and 99.0% (fenbendazole-piperonyl butoxide). The in-vitro S-oxidation of fenbendazole and fenbendazole sulphoxide was studied using microsomal preparations from rat liver. Piperonyl butoxide inhibited significantly the sulphoxidation and sulphonation of fenbendazole. It was concluded that piperonyl butoxide inhibited the oxidative conversion of fenbendazole into inactive metabolites and this resulted in a potentiated anthelmintic action.

Animals↗

Reproductive and neurobehavioural effects in three-generation toxicity study of piperonyl butoxide administered to mice.

Piperonyl butoxide (PB) was administered continuously to mice from 5 weeks of age in the F0 generation to weaning of the F2 generation. PB was administered in the diet at levels of 0 (control), 0.1, 0.2, 0.4 and 0.8%. Selected reproductive, developmental and behavioural parameters were measured. Litter size and litter weight were reduced in higher-dosed groups, and the body weight of the pups in the lactation period was reduced in dosed pups in each generation. The survival index at postnatal day 21 of the group receiving 0.8% PB was reduced in each generation. The developmental and behavioural parameters in the lactation period were little different from those of the controls, apart from olfactory orientation in the F1 generation. However, in the F2 generation mice, surface righting, cliff avoidance and olfactory orientation were adversely affected in treatment groups. The results suggest that PB had adverse effects on reproductive, developmental and behavioural parameters of mice, with increasing effects in subsequent generations of offspring.

Administration, Oral↗

Effect of piperonyl butoxide on organic anion and cation transport in rabbit kidneys.

Piperonyl butoxide has been shown to reduce accumulation of cephaloridine in rabbit renal cortex; however, the mechanism responsible for this effect remains unclear. Cephaloridine is a zwitterion and its accumulation in renal cortex has been suggested to be regulated by both organic anion and cation transport systems. Thus, it was of interest to determine the effect of piperonyl butoxide on renal transport of p-aminohippurate (PAH, an organic anion) and tetraethylammonium (TEA, an organic cation). Although pretreatment with piperonyl butoxide markedly inhibited renal cortical uptake of cephaloridine, the same treatment had less inhibitory effect on either PAH or TEA uptake. Efflux of PAH from preloaded renal cortical slices was enhanced by pretreatment with piperonyl butoxide; however, TEA efflux was unaffected. Thus, piperonyl butoxide appears to have effects on renal membrane functions which result in differential effects on PAH, TEA, and cephaloridine transport.

Aminohippuric Acids↗

Reproductive and neurobehavioural effects of piperonyl butoxide administered to mice in the diet.

Piperonyl butoxide was given in the diet to mice to provide levels of 0 (control), 0.01, 0.03 and 0.09% from 5 weeks of age of the F(0) generation to 9 weeks of age of the F(1) generation, and selected reproductive and neurobehavioural parameters were measured. There were no adverse effects of piperonyl butoxide on either litter size, litter weight or sex ratio at birth. The average body weight of male offspring was significantly increased in the middle-dose group at post-natal days 4 and 7 during lactation. That of female offspring was significantly increased in the middle-dose group at post-natal days 7 and 14 during lactation. In behavioural developmental parameters, surface righting at post-natal day 7 was significantly delayed in the higher-dose groups in male offspring, and those effects were significantly dose related (p < 0.01). Olfactory orientation at post-natal day 14 was significantly depressed in the higher-dose groups in male offspring, and those effects were significantly dose related (p < 0.01). For movement activity of exploratory behaviour at 9 weeks of age of the F(1) generation, the total distance of males was significantly increased in the higher-dose groups, and those effects showed a dose-related manner (p < 0.01). Average distance and speed were significantly increased in the high-dose group, and those effects showed a dose-related manner (p < 0.01 in each). The dose levels of piperonyl butoxide in the present study produced some adverse effects in reproductive and neurobehavioural parameters in mice.

Animals↗

Effect of piperonyl butoxide on disposition of di-2-ethylhexyl phthalate by rainbow trout.

1. Piperonyl butoxide in vitro inhibits the oxidation and hydrolysis of di-2-ethylhexyl phthalate, and the hydrolysis of the butyl ester of 2,4-dichloro-phenoxyacetic acid by liver homogenate fractions and serum from rainbow trout. 2. The rates of oxidation and hydrolysis of di-2-ethylhexyl phthalate by liver homogenates from rainbow trout pre-exposed to piperonyl butoxide (1 mg/l) were considerably lower than those by liver homogenates from control trout. 3. Disposition of di-2-ethylhexyl [14C]phthalate in rainbow trout in vivo was modified by pre-exposure to piperonyl butoxide. The piperonyl butoxide-treated trout had lower levels of 14C in bile and higher levels of 14C in blood and muscle than control trout. 4. Muscle of control and piperonyl butoxide-exposed trout showed similar concentrations of mono-2-ethylhexyl phthalate but the concentration of di-2-ethylhexyl phthalate in muscle from piperonyl butoxide-exposed trout was three times the control value.

Animals↗

Bioassay of piperonyl butoxide for possible carcinogenicity (CAS No. 51-03-6).

A bioassay of technical-grade piperonyl butoxide for possible carcinogenicity was conducted by administering the test chemical in feed to Fischer 344 rats and B6C3F1 mice. Groups of 50 rats of each sex were administered piperonyl butoxide in the diet at one of two doses, either 5,000 or 10,000 ppm, for 107 weeks. Matched controls consisted of 20 untreated rats of each sex. All surviving rats were killed at the end of the period of administration of the test chemical. Groups of 50 mice of each sex were initially administered piperonyl butoxide at one of two doses, either 2,500 or 5,000 ppm. After week 30, the doses for the mice were reduced to 500 and 2,000 ppm, respectively, and administration of the test chemical at the lowered doses was continued for 82 weeks. The time-weighted average doses for the mice were either 1,036 or 2,804 ppm. Matched controls consisted of 20 untreated mice of each sex. All surviving mice were killed at the end of the period of administration of the test chemical. Mean body weights of dosed groups of rats and mice of each sex were lower than those of corresponding control groups, and the depressions in body weights were dose related. Survival of the rats and mice was unaffected by the piperonyl butoxide and was 80% or greater in all groups at week 90 of the bioassay; thus, sufficient numbers of dosed and control rats and mice of each sex were at risk for the development of late-appearing tumors. In female rats, lymphomas occurred at incidences that were dose related (P=0.007); in a direct comparison, the incidence of the tumor in the high-dose group was higher (P=0.020) than that in the control group (controls 1/20, low-dose 7/50, high-dose 15/50). However, the incidence of lymphomas, leukemias, and reticuloses in historical-control female Fischer 344 rats at the same laboratory was 19/191 (10%). These historical-control groups include one with an incidence of animals with lymphoma or leukemia of 7/20 (35%) and another with an incidence of 6/20 (30%). Thus, the incidence of lymphomas in the control female rats of the present bioassay may have been abnormally low, and the occurrence of the higher incidence in the dosed groups cannot be clearly related to administration of piperonyl butoxide. In the male mice, adenomas of the lacrimal gland occurred at incidences that were dose related (P=0.023), but in direct comparisons the incidences in the individual dosed groups were not significantly higher than that in the control group (controls 0/20, low-dose 0/49, high-dose 4/50); thus, the occurrence of this tumor in the male mice was not clearly related to administration of the test chemical. It is concluded that under the conditions of this bioassay, piperonyl butoxide was not carcinogenic for Fischer 344 rats or B6C3F1 mice.

Journal Article↗

Uroporphyrin accumulation produced by halogenated biphenyls in chick-embryo hepatocytes. Reversal of the accumulation by piperonyl butoxide.

Cultures of chick-embryo hepatocytes were used to study the mechanism by which 3,4,3',4'-tetrachlorobiphenyl and 2,4,5,3',4'-pentabromobiphenyl cause accumulation of uroporphyrin. In a previous paper, an isoenzyme of cytochrome P-450 induced by 3-methylcholanthrene had been implicated in this process [Sinclair, Bement, Bonkovsky & Sinclair (1984) Biochem. J. 222, 737-748]. Cells treated with 3,4,3',4'-tetrachlorobiphenyl and 5-aminolaevulinate accumulated uroporphyrin and heptacarboxyporphyrin, whereas similarly treated cells accumulated protoporphyrin immediately after piperonyl butoxide was added. Piperonyl butoxide also restored haem synthesis as detected by incorporation of radioactive 5-aminolaevulinate into haem, and decrease in drug-induced 5-aminolaevulinate synthase activity. The restoration of synthesis of protoporphyrin and haem by piperonyl butoxide was not affected by addition of cycloheximide, indicating recovery was probably not due to protein synthesis de novo. Piperonyl butoxide also reversed uroporphyrin accumulation caused by 3,4,5,3',4',5'-hexachlorobiphenyl, mixtures of other halogenated biphenyls, lindane, parathion, nifedipine and verapamil. The effect of piperonyl butoxide was probably not due to inhibition of metabolism of these compounds, since the hexachlorobiphenyl was scarcely metabolized. Other methylenedioxyphenyl compounds, as well as ellipticine and acetylaminofluorene, also reversed the uroporphyrin accumulation caused by 3,4,3',4'-tetrachlorobiphenyl. SKF-525A (2-dimethylaminoethyl-2,2-diphenyl valerate) did not reverse the uroporphyrin accumulation caused by the halogenated biphenyls, but did reverse that caused by phenobarbital and propylisopropylacetamide. We conclude that the mechanism of the uroporphyrin accumulation cannot be due to covalent binding of activated metabolites of halogenated compounds to uroporphyrinogen decarboxylase.

2-Acetylaminofluorene↗